Expert Review of Pharmacoeconomics & Outcomes Research

(The TQCC of Expert Review of Pharmacoeconomics & Outcomes Research is 3. The table below lists those papers that are above that threshold based on CrossRef citation counts [max. 250 papers]. The publications cover those that have been published in the past four years, i.e., from 2020-02-01 to 2024-02-01.)
Burden and socioeconomics of asthma, allergic rhinitis, atopic dermatitis and food allergy132
Potential approaches for the pricing of cancer medicines across Europe to enhance the sustainability of healthcare systems and the implications43
An overview of the time trade-off method: concept, foundation, and the evaluation of distorting factors in putting a value on health39
Real-world reduction in healthcare resource utilization following treatment of opioid use disorder with reSET-O, a novel prescription digital therapeutic34
Organizational measures aiming to combat COVID-19 in the Russian Federation: the first experience32
Distinguishing features in the assessment of mHealth apps30
Tools to assess the quality of life in patients with Parkinson’s disease: a systematic review27
Cost-effectiveness analyses of breast cancer medications use in developing countries: a systematic review27
Burden of disease and costs associated with type 2 diabetes in emerging and established markets: systematic review analyses25
First-line atezolizumab plus chemotherapy in advanced non-squamous non-small cell lung cancer: a cost-effectiveness analysis from China22
Will the Markov model and partitioned survival model lead to different results? A review of recent economic evidence of cancer treatments20
Health-related quality of life in patients with chronic kidney disease20
Evaluation instruments for executive functions in children and adolescents: a systematic review16
Valuing health outcomes: developing better defaults based on health opportunity costs14
Cost-effectiveness of adding durvalumab to first-line chemotherapy for extensive-stage small-cell lung cancer in China14
The transferability of health technology assessment: the European perspective with focus on central and Eastern European countries13
Prevalence of chronic respiratory morbidity, length of stay, inpatient readmissions, and costs among extremely preterm infants with bronchopulmonary dysplasia13
Resource utilization, work productivity and costs in patients with hidradenitis suppurativa: a cost-of-illness study12
Gap analysis in manufacturing, innovation and marketing of medical devices in the Asia-Pacific region12
Outcome measures for physical fatigue in individuals with multiple sclerosis: a systematic review12
Cost-effectiveness of using a 20-valent pneumococcal conjugate vaccine to directly protect adults in England at elevated risk of pneumococcal disease12
Challenges in demonstrating the value of disease-modifying therapies for Alzheimer’s disease12
Economic evaluation of a multimodal intervention in pre-frail and frail older people with diabetes mellitus: the MID-FRAIL project11
A comparison of measurement properties between UK SF-6D and English EQ-5D-5L and Thai EQ-5D-5L value sets in general Thai population11
Comparative efficacy and safety of rimegepant, ubrogepant, and lasmiditan for acute treatment of migraine: a network meta-analysis11
Cost-effectiveness of pertuzumab and trastuzumab biosimilar combination therapy as initial treatment for HER2-positive metastatic breast cancer in Singapore11
Burden of communicable diseases and cost of illness: Asia pacific region11
‘Without data, you’re just another person with an opinion’10
The cost-effectiveness of once-weekly semaglutide compared with other GLP-1 receptor agonists in type 2 Diabetes: a systematic literature review10
The pharmacoeconomic impact of follitropin alpha biosimilars in IVF therapy in Europe: a report of the literature10
Design of a health-economic Markov model to assess cost-effectiveness and budget impact of the prevention and treatment of depressive disorder9
Cost-utility analysis and budget impact of benralizumab as add-on therapy to standard care for severe eosinophilic asthma in Colombia9
The efficacy and economic evaluation of roxadustat treatment for anemia in patients with kidney disease not receiving dialysis9
How do biosimilars sustain value, affordability, and access to oncology care?9
Artificial intelligence in outcomes research: a systematic scoping review8
Economic burden of comorbidities among COPD Patients hospitalized for acute exacerbations: an analysis of a commercially insured population8
Can we achieve affordable cancer medicine prices? Developing a pathway for change8
Factors associated with the healthcare expenditures of patients with multiple sclerosis in urban areas of China estimated by a generalized estimating equation7
Productivity loss/gain in cost-effectiveness analyses for vaccines: a systematic review7
Understanding long-listed pharmaceutical products without competition in South Korea: policy implications in managing generic entrants and pharmaceutical expenditures7
Cost of illness in multiple sclerosis by disease characteristics – A review of reviews7
Trends in the pricing and reimbursement of new anticancer drugs in South Korea: an analysis of listed anticancer drugs during the past three years7
Estimating the economic consequences of substance use and substance use disorders7
Adapting health technology assessment for drugs, medical devices, and health programs: Methodological considerations from the Indian experience7
Elderly individuals with diabetes and foot ulcer have a probability for healing despite extensive comorbidity and dependency7
Costs of medication use among patients with juvenile idiopathic arthritis in the Dutch healthcare system7
Cannabis use among Canadian adults with cancer (2007–2016): results from a national survey7
Evidence of long-term real-world reduction in healthcare resource utilization following treatment of opioid use disorder with reSET-O, a novel prescription digital therapeutic7
Cost-effectiveness of osimertinib versus standard EGFR-TKI as first-line treatment for locally advanced or metastatic EGFR mutation-positive non-small cell lung cancer in Australia7
Acceptability and willingness to pay for a hypothetical vaccine against SARS CoV-2 by the Brazilian consumer: a cross-sectional study and the implications7
Cost-utility of dapagliflozin plus standard treatment compared to standard treatment for the management of heart failure with reduced ejection fraction in Colombia6
Not cost-effective at zero price: valuing and paying for combination therapies in cancer6
Cost-effectiveness of trifluridine/tipiracil as a third-line treatment of metastatic gastric cancer, including adenocarcinoma of the gastrohesophageal junction, among patients previously treated in Gr6
Barriers and facilitators of exploiting the potential of value-added medicines6
Economic burden associated with stroke in India: insights from national sample survey 2017-186
Cost-utility analysis of dupilumab add on therapy versus standard therapy in adolescents and adults for severe asthma in Colombia6
Cost-effectiveness analysis of donafenib versus lenvatinib for first-line treatment of unresectable or metastatic hepatocellular carcinoma6
The current state of patient access to new drugs in South Korea under the positive list system: evaluation of the changes since the new review pathways6
The impact of changing the funding model for genetic diagnostics and improved access to personalized medicine in oncology6
Pembrolizumab plus lenvatinib or axitinib compared to nivolumab plus ipilimumab or cabozantinib in advanced renal cell carcinoma: a number needed to treat analysis6
Impact on hospitalizations of long-term versus short-term therapy with sodium zirconium cyclosilicate during routine outpatient care of patients with hyperkalemia: the recognize I study6
A review of quality-of-life in elderly osteoarthritis6
Cost-effectiveness analysis of olaparib and niraparib as maintenance therapy for women with recurrent platinum-sensitive ovarian cancer6
Cost-effectiveness of olaparib maintenance therapy when used with and without restriction by BRCA1/2 mutation status for platinum-sensitive relapsed ovarian cancer6
Cost of patients with hemophilia A treated with standard half-life or extended half-life FVIII in Spain6
The challenge of sustainability in healthcare systems: economic and organizational impact of subcutaneous formulations for rituximab and trastuzumab in onco-hematology6
Burden of Hodgkin and non-Hodgkin lymphoma in Spain over a 10-year period: productivity losses due to premature mortality6
Disease burden on health care by pain severity and usual analgesic treatment in patients with symptomatic osteoarthritis: a Spanish nationwide health survey6
An update on the economic burden of type 2 diabetes mellitus in China6
Cardiovascular outcome trials of glucose-lowering therapies5
Durvalumab consolidation therapy in patients with stage III non-small cell lung cancer after concurrent chemoradiation: a China-based cost-effectiveness analysis5
Cost-effectiveness analysis of molecular diagnosis by next-generation sequencing versus sequential single testing in metastatic non-small cell lung cancer patients from a south Spanish hospital perspe5
Cost-effectiveness of aripiprazole orally disintegrating tablets in the treatment of schizophrenia in China5
Cost-effectiveness analyses of targeted therapy and immunotherapy for advanced non-small cell lung cancer in the United States: a systematic review5
Cost-effectiveness of treatments for HER2-positive metastatic breast cancer and associated metastases: an overview of systematic reviews5
Short-term societal economic burden of first-incident type 2 diabetes-related complications – a nationwide cohort study5
The costs of treatment resistant depression: evidence from a survey among Italian patients5
Pharmacoeconomics of obesity in China: a scoping review5
Cost-effectiveness analyses comparing cemented, cementless, hybrid and reverse hybrid fixation in total hip arthroplasty: a systematic overview and critical appraisal of the current evidence5
The economic value of knowing BRCA status: universal BRCA testing for breast cancer prevention5
Budget impact analysis of subcutaneous trastuzumab compared to intravenous trastuzumab in Saudi HER2-positive breast cancer patients5
Exploring the consistency of the SF-6Dv2 in a breast cancer population5
Cost-effectiveness analysis of antihypertensive triple combination therapy among patients enrolled in a Medicare advantage plan5
Direct medical costs of breast cancer in Jordan: cost drivers and predictors5
Burden of illness the first year after diagnosed bladder dysfunction among people with spinal cord injury or multiple sclerosis – a Danish register study4
Letter to the editor on ‘cognitive behavior therapy for health anxiety: systematic review and meta-analysis of clinical efficacy and health economic outcomes’4
Prevalence and direct costs of potentially inappropriate prescriptions in France: a population-based study4
Assessing the pricing and benefits of oncology products: an update4
A systematic review and meta-regression of studies eliciting willingness-to-pay per quality-adjusted life year in the general population4
Preference of young adults for COVID-19 vaccination in the United Kingdom: a discrete choice experiment4
Cost-effectiveness analysis of apixaban compared to other direct oral anticoagulants for prevention of stroke in Austrian atrial fibrillation patients4
Cost-effectiveness analysis of tofacitinib compared with adalimumab and etanercept in the treatment of severe active rheumatoid arthritis; Iranian experience4
Impact of surgical instrumentation on hospital length of stay and cost of total knee arthroplasty4
Assessment of women’s treatment preferences for vasomotor symptoms due to menopause4
Early technology assessment of using whole genome sequencing in personalized oncology4
The Economic and societal burden of multiple sclerosis on lebanese society: a cost-of-illness and quality of life study protocol4
In-hospital economic burden of anastomotic leakage after colorectal anastomosis surgery: a real-world cost analysis in Italy4
Healthcare resource utilization in patients with newly diagnosed atrial fibrillation in the United States4
Incremental cost-effectiveness analysis of tyrosine kinase inhibitors in advanced non-small cell lung cancer with mutations of the epidermal growth factor receptor in Colombia4
Pharmaco-utilization of biologic drugs in patients affected by psoriasis, psoriatic arthritis and ankylosing spondylitis in an Italian real-world setting4
Cost-related nonadherence for prescription medications: a cross-sectional study in Jordan4
Cost of fremanezumab, erenumab, galcanezumab and onabotulinumtoxinA associated adverse events, for migraine prophylaxis in Spain4
How can societal culture and values influence health and rehabilitation outcomes?4
Considering potential solutions for limitations and challenges in the health economic evaluation of gene therapies4
The impact of fibrodysplasia ossificans progressiva (FOP) on patients and their family members: results from an international burden of illness survey4
A pharmacovigilance study to quantify the strength of association between the combination of antimalarial drugs and azithromycin and cardiac arrhythmias: implications for the treatment of COVID-19.4
Value elements and methods of value-based pricing for drugs in Japan: a systematic review4
Cost-utility analysis of ceftazidime-avibactam versus colistin-meropenem in the treatment of infections due to Carbapenem-resistant Klebsiella pneumoniae in Colombia4
Economic evaluation of adjuvant trastuzumab therapy for HER2-positive early-stage breast cancer: systematic review and quality assessment4
A review of caregiver costs included in cost-of-illness studies3
Treatment patterns, adverse events, and direct and indirect economic burden in a privately insured population of patients with HR+/HER2– metastatic breast cancer in the United States3
Evaluation of quality of pharmacoeconomic studies involved in traditional Chinese medicine in China3
A pre-vaccine analysis using the Health Belief Model to explain parents’ willingness to vaccinate (WTV) their children in the United States: implications for vaccination programs3
Cost-effectiveness of pharmacist-led care versus usual care in type 2 diabetic Jordanians: a Markov modeling of cardiovascular diseases prevention3
All-cause community acquired pneumonia cost by age and risk in real-world conditions of care in Spain3
Cost-effectiveness analysis of nab-paclitaxel plus gemcitabine versus folfirinox in the treatment of metastatic pancreatic cancer in china3
Economic evaluation of reproductive carrier screening for recessive genetic conditions: a systematic review3
A systematic review of cost-effectiveness analyses of continuous versus intermittent renal replacement therapy in acute kidney injury3
Patient preferences for elagolix and leuprolide for treating endometriosis-related pain in the United States3
The impact of statistical properties of incremental monetary net benefit and incremental cost-effectiveness ratio on health economic modeling choices3
Barriers to implementing pharmacoeconomics: interview study3
Bringing the patient’s perspectives forward in drug development and health-care evaluation3
Characterization of health-related quality of life based on the EQ-5D-5L questionnaire in head-and-neck cancer patients undergoing modern radiotherapy3
Budget impact analysis of medicines: estimated values versus real-world evidence and the implications3
A systematic review of cost-effectiveness analyses across the acute kidney injury landscape3
Assessment of the properties of the EQ-5D-5L in patients with type 2 diabetes mellitus: a systematic review and meta-analysis3
Assessing the value contribution of bimekizumab for the treatment of moderate-to-severe psoriasis using a multidisciplinary reflective multi-criteria decision analysis3
A landscape analysis and discussion of value of gene therapies for sickle cell disease3
Burden of depression among Canadian adults with cancer; results from a national survey3
Pharmacoeconomic evaluation of dipeptidyl peptidase-4 inhibitors for the treatment of type 2 diabetes mellitus: a systematic literature review3
Cost-utility analysis of the anti-TNF therapy for rheumatoid arthritis in a real-world based model3
Moving beyond the stage: how characteristics at diagnosis dictate treatment and treatment-related quality of life year losses for women with early stage invasive breast cancer3
The value of communicating with patients in their first language3
Summary of the 2020 AHRQ research meeting on ‘advancing methods of implementing and evaluating patient experience improvement using consumer assessment of healthcare providers and systems (CAHPS®) sur3
Cost-utility analysis of stereotactic body radiotherapy plus cetuximab in previously irradiated recurrent squamous cell carcinoma of the head and neck3
Patient associations and clinical oncology research: how much does a patient’s voice really matter?3
Burden of disease and costs of infections associated with cardiac implantable electronic devices3
Determination of the economically justifiable price of cenobamate in the treatment of focal-onset seizures in adult patients with drug-resistant epilepsy in Spain3
Tenecteplase in managing acute ischemic stroke: a long-term cost–utility analysis in Iran3